Pharmaceutical Executive April 16, 2024
Amid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their strategic planning process—and do it now.
As evidenced by recent headlines, the Inflation Reduction Act (IRA) continues to drive tremendous change across the industry, reshaping healthcare regulations and introducing new challenges and pricing pressures for biopharmaceutical companies.
Given the rapidly evolving landscape, drug manufacturers and their partners should closely monitor the latest regulatory activity —from the ongoing negotiations as part of the Medicare Drug Price Negotiation (MDPN) program to inflation penalties and Medicare Part D benefit redesign provisions. More importantly, biopharma companies need to understand the potential impact of those changes—as well as those on the horizon—and take actions to...
Today's Sponsors
Today's Sponsor